Objectives: Refractory major depressive disorder (MDD) is a serious problem leading to a heavy economic burden. Antipsychotic augmentation treatment with aripiprazole and quetiapine is approved for MDD patients and can achieve a high remission rate. This study aimed to examine how psychiatrists in Taiwan choose medications and how that choice is influenced by health insurance payments and administrative policy. Design: Descriptive study. Outcome measures: Eight questions about the choice of treatment strategy and atypical antipsychotics, and the reason to choose aripiprazole. Intervention: We designed an augmentation strategy questionnaire for psychiatrists whose patients had a poor response to antidepressants, and handed it out during the annual meeting of the Taiwanese Society of Psychiatry in October 2012. It included eight questions addressing the choice of treatment strategy and atypical antipsychotics, and the reason whether or not to choose aripiprazole as the augmentation antipsychotic. Results: Choosing antipsychotic augmentation therapy or switching to other antidepressant strategies for MDD patients with an inadequate response to antidepressants was common with a similar probability (76.1% vs 76.4%). The most frequently used antipsychotics were aripiprazole and quetiapine, however a substantial number of psychiatrists chose olanzapine, risperidone, and sulpiride. The major reason for not choosing aripiprazole was cost (52.1%), followed by insurance official policy audit and deletion in the claims review system (30.1%).
Introduction
Major depressive disorder (MDD) is a common and recurrent mental illness with a lifetime prevalence of 5%-12% in adult men and 9%-26% in adult women. In spite of recent advances in psychopharmacology, approximately 60% of patients with MDD do not achieve an adequate response or remission to initial antidepressant therapy (ADT) even with adequate dose and duration. 1 Common strategies adopted for nonresponders to ADT include switching to other antidepressants, combining therapy with antidepressants of another class, and augmentation strategies with atypical antipsychotics, lithium, or thyroid hormone.
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hsu et al conducted on the actual choices of psychiatrists for nonre sponders to ADT.
The prescribing behavior of physicians is influenced by many factors, including evidencebased medical knowl edge, training and continuous education, and largely by health insurance and reimbursement or payment policies. [6] [7] [8] The aim of this study was to examine how Taiwanese psychiatrists prescribe medication and how they are influ enced by health insurance payments and admini strative policy.
Methods
This descriptive study used an innovative questionnaire for Taiwanese psychiatrists on augmentation strategy for MDD patients with an inadequate response to ADT. The aim of this questionnaire was to examine the influence of health insurance payments and administrative policy on the prescribing behavior of Taiwanese psychiatrists. The first question asked how many MDD outpatients per month each Taiwanese psychiatrists treated. The second question asked about the percentage of poor responders to ADT, and the third question asked about the remission rate of MDD. The fourth question asked about the strategies used for the poor responders to ADT, and the fifth question asked which antipsychotics were chosen for antipsychotic augmenta tion therapy. The sixth and seventh questions asked why and why not aripiprazole was chosen as the augmentation antipsychotic. The eighth question asked why augmentation antipsychotics were not chosen. We handed out the question naire during the annual meeting of the Taiwanese Society of Psychiatry in October 2012.
Statistical analysis
Outpatient visits per month, percentage of poor respond ers to ADT, remission rate, the strategies used for the poor responders to ADT, and choice of augmentation antipsy chotics were presented with numbers and percentages. The answers to questions 4-8 according to the number of MDD outpatients per month were compared using chisquare and Fisher's exact tests. Analysis of covariance (ANCOVA) was used to analyze the relationship between the answers to questions 4-8 and the number of MDD outpatients per month after including poor response proportion and remis sion rate as covariates. Multiple logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the correlate variables associated with aripiprazole and quetiapine. The IBM SPSS Statistics version 22 The data in Table 2 reveals several statistical differ ences among groups of those who treated different numbers of MDD patients per month (100, 101-200, and 200), in the antipsychotics chosen, the reasons why they did not choose aripiprazole, and the reasons why they did not choose antipsychotics for augmentation. For example, the reason why psychiatrists in the group of 101-200 treated patients/ month, chose not to augment with antipsychotics due to "health insurance payment audit and deletion", is signifi cantly higher than other groups (76 in 129, 59.4%, P0.001 in ANCOVA) ( Table 2 ).
In further analysis by the number of patients the psychia trists treated per month, those who saw 101-200 persons/ month were more likely to choose quetiapine and olanzapine as augmentation strategy, but those who saw more than 200 persons/month were less likely to choose quetiapine and olanzapine as augmentation strategy. There was no differ ence in choosing aripiprazole as the augmentation strategy between the groups (Table 3) .
Discussion
Treatmentresistant depression is associated with extensive use of general and psychiatric medical services, which poses substantial economic burden and work loss costs. 9, 10 The pre scribing behavior of psychiatrists may influence the outcomes of refractory MDD and cause a delay in the use of adequate antipsychotic augmentation therapy. It is important therefore for health policy makers to understand the prescribing behav iors and modify the insurance policy accordingly.
The national health care system in Taiwan, known as the National Health Insurance (NHI) program, was instituted in 1995. The NHI program is a singlepayer compulsory social insurance plan which centralizes the disbursement of health care funds. 11, 12 The system promises equal access to health care for all citizens, and the population coverage had reached 99% by the end of 2004. 13, 14 Although patient satisfaction with the NHI program was reported to be more than 80% in 2011, 15 doctors have reported dissatisfaction because of instability in NHI regulations, a complicated medical claims system, and excessive working hours. 16 Doctors can be heavily penalized for a wide variety of reasons such as seeing too many patients or offering too many services even if they were appropriate under a budgetreduction scenario and reducedpayment physician payment policy and claims review system. 17 In Taiwan, the NHI payment policy adopts a unique way in the denial of prescriptions payment, which is called "insurance policy audit and deletion of payments". The auditors act by "posthoc" denial, or deletion, of payment for the medications. For example, while some health care providers (including psychiatrists) prescribe medications costlier than those prescribed daily by other peer health care providers, auditors could delete the payment for these medications. This doesn't just mean that the NHI denied the payment per se, but also means a 100fold penalty, that is, 100fold of the price of the denied medications must be paid back to the NHI by the health care providers. [18] [19] [20] The sampling rate of cases for auditing is onefifteenth (6.67%) of the medical cases submitted monthly by individual health care providers. 21 MDD is one of the major mental illnesses treated by Taiwanese psychiatrists, many of whom agree that an inadequate poor response to ADT is common. Although 50%-60% of patients respond to firstline treatment, only 35%-40% of patients were reported to experience a remis sion of symptoms during an initial 8week trial. 1 In Taiwan, the inadequate response rate has been reported to be 30%. Most psychiatrists in Taiwan agree that around 60% of MDD patients can achieve remission, which is close to that reported with venlafaxine (59.3%), and higher than that reported in previous studies with conventional antidepressants (ie, paroxetine, citalopram, sertraline, fluoxetine, mirtazapine, or other treatments), 22 which may imply that Taiwanese psychiatrists overestimate the MDD remission rate.
Other than medical knowledge and training, physician prescribing behavior is largely influenced by pharmaceutical promotions, 23 health insurance payments, and administrative policy. As previously reported, health insurance policy can jeopardize patient benefits when physicians are required to conform to the financedriven regulatory rules of health insurance companies. 7, 8, 24 Switching to venlafaxine, for example, has been shown to have a higher response rate after selective serotonin reuptake inhibitor (SSRI) failure. Three randomized controlled trials demonstrated that aripiprazole augmentation is useful for antidepressant non responders, and that it should be reserved for nonresponders after 6 weeks of adequate ADT. 25, 26 There is currently no con sensus on the duration of aripiprazole augmentation, however current American Psychiatric Association MDD guidelines recommend the same dose used for the acute phase as in the continuation and maintenance phases. 27 The most common adverse effect of aripiprazole is akathisia, which occurs in about 23.1% of the patients treated with aripiprazole, 25 and can be treated with propranolol. Many Taiwanese psychia trists choose aripiprazole and quetiapine as augmentation antipsychotics, however up to 30% of Taiwanese psychia trists still choose offlabel olanzapine (34.6%), risperidone (30.2%), and sulpiride (27.4%). In Taiwan, psychiatrists are allowed to prescribe medications for offlabel use, [28] [29] [30] [31] but offlabel use of prescriptions are one of the exclusion criteria for drug relief in the Taiwan Drug Hazard Relief Act, which was enacted in 2000. 32, 33 The main reasons why psychiatrists do not choose ari piprazole are price, insurance audit and deletion, and adverse effects. Aripiprazole costs US$0.33 per mg in Taiwan, and therefore a dose ranging from 2-10 mg/d costs US$0.66-3.30 per day. Whereas, antidepressants cost US$0.14-0.95 per tablet for SSRI, and US$0.90-1.07 per tablet for (serotonin norepinephrine reuptake inhibitor) SNRI. So an adequate dose of SSRI costs US$0.14-0.95 per day and US$2.70-3.20 per day for SNRI. 34 The switching strategy is cheaper than augmentation strategy. In 2004, the average daily drug price for depressive outpatients in Taiwan was estimated to be US$1.3±1.316. 35 Insurance payment is an important concern for Taiwan psychiatrists. If the prescription is audited and deleted in outpatients, the penalty is up to 100fold the medication price. 20 We speculate that insurance audit and deletion is the main reason why Taiwanese psychiatrists do not choose aripipra zole as an augmentation strategy. In contrast to the American Psychiatric Association's willingness to sue insurers over American Medical Association's Current Procedural Termi nology code violations, 36 the Taiwanese Society of Psychiatry has taken little action against insurance audit and deletion.
Few previous studies have discussed psychiatrists' decisionmaking. In one study concerning the prescrip tion of benzodiazepines, the decisionmaking was found to be influenced by concerns of fear of supply, initiating substance abuse, or even diversions in patients, especially when facing time limits and patient manipulation, however insurance coverage issues were not mentioned. 37 Similar to a study which reported that the prescription of nonsteroid antiinflammatory drugs (NSAIDs) or NSAIDs with gas troprotective therapy to the elderly with osteoarthritis was influenced by the reimbursement policy in Canada, 7 the prescribing behavior by Taiwanese psychiatrists for antipsy chotic augmentation seems to be affected by health insurance payment policy.
The response to placebo in antidepressant drug trials for MDD is highly variable and has increased significantly in recent years. 38 Two main mechanisms underlie the effect of placebo administration: conditioned reflexes, which are subconscious, and the patient's expectations, which are conscious. Other factors in placebo administration relate to the doctor's influence on the patient's attitude to his or her disease. This can be referred to as the "context effect". 39 Placebo effects may explain why offlabel use of atypical antipsychotics is common among Taiwanese psychiatrists.
The main limitation of this study is lack of demo graphic data, for most of the psychiatrists did not offer their detailed personal information. However, the total numbers of psychiatrists was nearly 1,436 in the year of the study, 2012, 40 therefore, nearly one in every five (22.56%) Taiwan psychiatrists responded to this questionnaire, which could be representative of this group.
Conclusion
Antipsychotic augmentation with aripiprazole and quetiapine is recommended for MDD patients with a poor response to ADT, however many Taiwanese psychiatrists still choose a switching strategy. Price and insurance audit and deletion affected the intention to prescribe aripiprazole. We suggest that prescribing behavior by Taiwan psychiatrists for antipsy chotic augmentation is affected by health insurance policy.
